Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade

(2017) Joost Dejaegher et al.   INTERNATIONAL JOURNAL OF CANCER

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Adult Glioblastoma

(2017) Brian M. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Oncolytic Viruses in Cancer Treatment

(2017) Sean E. Lawler et al.   JAMA Oncology

The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells

(2017) Alessandra Audia et al.   Frontiers in Oncology

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Oncolytic herpes simplex virus interactions with the host immune system

(2016) Dipongkor Saha et al.   Current Opinion in Virology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Exploring the antitumor effect of virus in malignant glioma

(2015)   DRUGS OF THE FUTURE

Cancer stem cells in glioblastoma

(2015) Justin D. Lathia et al.   GENES & DEVELOPMENT

Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV

(2015) Lucia Mazzacurati et al.   MOLECULAR THERAPY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth

(2015) Wenchao Zhou et al.   NATURE CELL BIOLOGY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Prospects of immune checkpoint modulators in the treatment of glioblastoma

(2015) Matthias Preusser et al.   Nature Reviews Neurology

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

(2015) D. A. Reardon et al.   Cancer Immunology Research

Designing herpes viruses as oncolytics

(2015) Cole Peters et al.   Molecular Therapy-Oncolytics

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Emerging treatment strategies for glioblastoma multiforme

(2014) S. K. Carlsson et al.   EMBO Molecular Medicine

Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma

(2014) Lei Lu et al.   JOURNAL OF NEURO-ONCOLOGY

Immunocompetent murine models for the study of glioblastoma immunotherapy

(2014) Taemin Oh et al.   Journal of Translational Medicine

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

(2014) Jianfang Ning et al.   Frontiers in Microbiology

Oncolytic Viruses and Their Application to Cancer Immunotherapy

(2014) E. A. Chiocca et al.   Cancer Immunology Research

Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates

(2014) Justin C. Roth et al.   Human Gene Therapy Clinical Development

Immunovirotherapy for glioblastoma

(2013) Jianfang Ning et al.   CELL CYCLE

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

(2013) T. A. Cheema et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models

(2012) B J Passer et al.   CANCER GENE THERAPY

In vivo models of primary brain tumors: pitfalls and perspectives

(2012) P. C. Huszthy et al.   NEURO-ONCOLOGY

Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells

(2011) H. Wakimoto et al.   NEURO-ONCOLOGY

Development of a novel mouse glioma model using lentiviral vectors

(2009) Tomotoshi Marumoto et al.   NATURE MEDICINE